Washington State House of Representatives Office of Program Research | BILL ANALYSIS |
Health Care & Wellness Committee |
HB 1667
This analysis was prepared by non-partisan legislative staff for the use of legislative members in their deliberations. This analysis is not a part of the legislation nor does it constitute a statement of legislative intent. |
Brief Description: Establishing the bleeding disorder collaborative for care.
Sponsors: Representatives Cody, Jinkins, Robinson and Tharinger.
Brief Summary of Bill |
|
Hearing Date: 2/17/15
Staff: Chris Blake (786-7392).
Background:
Bleeding Disorders.
When there is an injury to blood vessels, platelets are activated and they adhere to the injured site and form a clot. Bleeding disorders are conditions in which there is a problem with the body's blood clotting process. There are several types of bleeding disorders that can affect the blood clotting process, including hemophilia and Von Willebrand disease.
Coordinated State Purchasing of Health Care.
The Health Care Authority is responsible for several programs that coordinate the purchasing of health care services. The Health Technology Assessment Program reviews scientific, evidence-based reports about the safety and effectiveness of medical devices, procedures, and tests and a clinical committee determines whether or not the state should pay for them. The Prescription Drug Program contracts for independent reviews of prescription drugs to compare the safety, efficacy, and effectiveness of drug classes from which recommendations are made by a clinical committee for the development of a preferred drug list. The Bree Collaborative identifies health care services that have substantial variations in practice patterns or high utilization trends and investigates evidence-based practices that will improve quality and reduce variation in the use of the services.
Summary of Bill:
The Bleeding Disorder Collaborative for Care (Collaborative) is established by the Health Care Authority (Authority). The Collaborative is comprised of:
three representatives of the Health Care Authority;
three representatives of the largest organization in Washington that represents patients with bleeding disorders;
two representatives of state designated bleeding disorder centers of excellence; and
two representatives of federally funded hemophilia treatment centers based in Washington.
The Collaborative is responsible for identifying and developing evidence-based practices to improve care to patients with bleeding disorders. Where evidence-based practices do not exist, the Collaborative will research and create the practices. The Collaborative may also consider research-based practices or emerging best practices. The Collaborative must recommend how to disseminate the evidence-based practices to health care professionals and provide them with options for using them in their practices. Lastly, the Collaborative must assist the Authority with the development of a cost-benefit analysis related to the use of the evidence-based practices in state-purchased health care programs.
The Authority must report to the Governor and the Legislature by September 1, 2016. The report must address the evidence-based practices that have been developed, the clinical and fiscal implications should they be implemented, and a strategy for publicizing the practices and having health care professionals use them in state-financed health care programs.
"Bleeding disorder" is defined as a condition involving the impairment of the body's blood clotting processes.
Legislative findings are made related to the nature of bleeding disorders, their effect on the lives of people with bleeding disorders, and the need for improved care and management of patients with bleeding disorders.
Appropriation: None.
Fiscal Note: Requested on February 12, 2015.
Effective Date: The bill takes effect 90 days after adjournment of the session in which the bill is passed.